ClinicalTrials.gg
CompletedNCT04991753Updated Aug 22, 2025Results posted

A Proof-of-concept Study of the Efficacy and Safety of Nipocalimab in Participants With Active Rheumatoid Arthritis

A Phase 2 interventional study of Placebo and Nipocalimab in Arthritis, Rheumatoid, sponsored by Janssen Research & Development, LLC. Completed at 28 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-22.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 90 studies in Arthritis, Rheumatoid by Johnson & Johnson — 1 open to participants now, 1 under way, none of them phase 3. Arthritis, Rheumatoid · Johnson & Johnson.

Enrollment
59th of 75
53 · median 210
Started
2021
with 1 other
Phase 2
16 of 90
none open now
Registered
88th of 90
by date

Among the 90 studies in Arthritis, Rheumatoid by Johnson & Johnson, this one is the 59th largest by enrollment of the 75 interventional ones that give a count, is one of 2 that started in 2021, is one of 16 in phase 2, and was the 88th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

1 of the 90 studies in Arthritis, Rheumatoid by Johnson & Johnson is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies in Arthritis, Rheumatoid by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of nipocalimab versus placebo in participants with moderate to severe active rheumatoid arthritis (RA).

Read the detailed description

RA is a chronic autoimmune inflammatory disorder of unknown etiology that occurs in approximately 1 percent (%) of the population. Nipocalimab (also referred to as JNJ-80202135 and M281) is a fully human aglycosylated immunoglobulin (Ig)G1 monoclonal antibody designed to selectively bind, saturate, and block the IgG binding site on the endogenous neonatal fragment crystallizable (Fc) receptor (FcRn). Nipocalimab has a unique mechanism of action whereby it blocks the IgG binding site on endogenous FcRn and is expected to decrease pathogenic IgG antibody concentrations. A significant involvement of pathogenic IgG antibodies has been demonstrated in autoimmune diseases including RA. The primary hypothesis is that treatment with nipocalimab intravenously (IV) every 2 weeks (q2w) is superior to placebo in participants with moderate to severe active rheumatoid arthritis (RA) as assessed by the mean change from baseline in the disease activity index score 28 using C-reactive Protein (DAS28-CRP) at Week 12. The study consists of a Screening Period (less than or equal to [\<=] 6 Weeks), Double-blind Treatment Period (12 Weeks), and a Safety Follow-up Period (6 Weeks). Key safety assessments will include adverse events (AEs), serious adverse events (SAEs), adverse events of special interests (AESIs), clinical laboratory safety tests (hematology, chemistry, and lipid profile), vital signs, and physical examination. The total duration of the study is up to 24 weeks.

03

Conditions studied

  • Arthritis, Rheumatoid
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of rheumatoid arthritis (RA) and meeting the 2010 American college of rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria for RA for at least 3 months before screening
  • Has moderate to severe active RA as defined by persistent disease activity with at least 6 swollen and 6 tender joints out of the 66/68-swollen and tender joint count at the time of screening and at baseline
  • Is positive for anti-citrullinated protein antibodies (ACPA) and/or rheumatoid factor (RF) at screening
  • Screening C-reactive protein (CRP) greater than or equal to (>=) 0.3 milligram per deciliter (mg/dL) by the central laboratory
  • A woman of must have a negative highly sensitive urine pregnancy test (beta-human chorionic gonadotropin [beta-hCG]) at screening and a negative urine (beta-hCG) pregnancy test at Week 0 prior to administration of study intervention

Exclusion criteria

Exclusion Criteria:

  • Has any confirmed or suspected clinical immunodeficiency syndrome not related to treatment of his/her RA or has a family history of congenital or hereditary immunodeficiency unless confirmed absent in the participant
  • Currently has a or has a history of malignancy within 3 years before screening (with the exception of localized basal cell carcinoma and/or squamous cell carcinoma skin cancer that has been adequately treated with no evidence of recurrence for at least 12 weeks before the first administration of study intervention or cervical carcinoma in situ that has been treated with no evidence of recurrence for at least 3 months before the first administration of study intervention)
  • Is (anatomically or functionally) asplenic
  • Has experienced myocardial infarction (MI), unstable ischemic heart disease, or stroke within 12 weeks of screening
  • Has other known inflammatory diseases that might confound the evaluations of benefit from nipocalimab therapy, including but not limited to ankylosing spondylitis, psoriatic arthritis, systemic lupus erythematosus, Lyme disease
  • Is currently taking immunoglobulin (Ig)G fragment crystallizable (Fc)-related protein therapeutics
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
53 participants (actual)

Study arms

  • Placebo comparator
    Group 1: Placebo

    Participants will receive placebo intravenously (IV) every 2 weeks (q2w) through Week 10 along with standard-of-care background therapy.

    Other: Placebo

  • Experimental
    Group 2: Nipocalimab

    Participants will receive nipocalimab IV q2w through Week 10 along with standard-of-care background therapy.

    Drug: Nipocalimab

Interventions

  • OtherPlacebo

    Placebo infusion will be administered intravenously.

  • Nipocalimab infusions will be administered intravenously.

    Also known as: JNJ-80202135, M281

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Disease Activity Index Score 28 Using C-reactive Protein (DAS28-CRP) at Week 12

    Change from baseline in DAS28-CRP at Week 12 were reported. The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity, and C-reactive protein (CRP; in milligrams per liter \[mg/L\]). The set of 28 joint count was based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. Score on the DAS28 ranged from 0 to 10, where higher scores indicated more disease activity. Negative changes from baseline indicated improvement of arthritis.

    Time frame: Baseline (Week 0), Week 12

Secondary outcomes

  1. Percentage of Participants Who Achieved American College of Rheumatology (ACR) 20 at Week 12

    Percentage of participants who achieved ACR20 at Week 12 were reported. ACR20 response is defined as: greater than or equal to (\>=)20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 millimeters \[mm\], 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function as measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP.

    Time frame: Week 12

  2. Percentage of Participants Who Achieved American College of Rheumatology (ACR) 50 at Week 12

    Percentage of participants who achieved ACR50 at Week 12 were reported. ACR50 response is defined as: \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function as measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP.

    Time frame: Week 12

  3. Percentage of Participants Who Achieved American College of Rheumatology (ACR) 70 at Week 12

    Percentage of participants who achieved ACR70 at Week 12 were reported. ACR70 response is defined as: \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function as measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP.

    Time frame: Week 12

  4. Percentage of Participants Who Achieved American College of Rheumatology (ACR) 90 at Week 12

    Percentage of participants who achieved ACR90 at Week 12 were reported. ACR90 response is defined as: \>=90% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=90% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function as measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP.

    Time frame: Week 12

  5. Percentage of Participants Who Achieved Disease Activity Index Score 28 Using C-reactive Protein (DAS28-CRP) Remission at Week 12

    Percentage of participants who achieved DAS28-CRP remission at Week 12 were reported. The DAS28 remission is defined as DAS28 -CRP value of less than (\<) 2.6 at Week 12. The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity, and CRP; in mg/L). The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, MCP1 to MCP5, PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. Score on the DAS28 ranged from 0 to 10, where higher scores indicated more disease activity. Negative changes from baseline indicated improvement of arthritis.

    Time frame: Week 12

  6. Percentage of Participants Who Achieved Disease Activity Index Score 28 Using C-reactive Protein (DAS28-CRP) Low Disease Activity (LDA) European League Against Rheumatism (EULAR) at Week 12

    Percentage of participants who achieved DAS28-CRP LDA EULAR at Week 12 were reported. The DAS28 LDA EULAR is defined as DAS28 -CRP value of less than or equal to (\<=) 3.2 at Week 12. The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity, and C-reactive protein (CRP; in mg/L). The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, MCP1 to MCP5, PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. Score on the DAS28 ranged from 0 to 10, where higher scores indicated more disease activity. Negative changes from baseline indicated improvement of arthritis.

    Time frame: Week 12

  7. Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Week 12

    Change from baseline in HAQ-DI score at Week 12 were reported. The HAQ-DI is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas: dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living, over the past week. Responses in each functional area were scored on a scale from 0 (indicating no difficulty) to 3 (inability to perform a task in that area). Overall score was computed as the sum of category scores and divided by the number of categories answered and ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability.

    Time frame: Baseline (Week 0), Week 12

  8. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)

    Percentage of participants with TEAEs were reported. An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs were defined as any AE occurring at or after the initial administration of study intervention through the safety follow-up visit (8 weeks after the last administration of study intervention).

    Time frame: From Week 0 up to 8 weeks post last dose at Week 10 (up to Week 18)

  9. Percentage of Participants With Treatment-emergent Serious Adverse Events (TESAEs)

    Percentage of participants with TESAEs were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/ incapacity, or resulted in congenital anomaly/birth defect. TESAEs were defined as any SAE occurring at or after the initial administration of study intervention through the safety follow-up visit (8 weeks after the last administration of study intervention).

    Time frame: From Week 0 up to 8 weeks post last dose at Week 10 (up to Week 18)

  10. Percentage of Participants With AEs Leading to Discontinuation of Study Intervention

    Percentage of participants with AEs leading to discontinuation of study intervention were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.

    Time frame: From Week 0 up to Week 10

  11. Percentage of Participants With Treatment-emergent Adverse Events of Special Interest (AESIs)

    Percentage of participants with TEAEs of special interest were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs were defined as any AE occurring at or after the initial administration of study intervention through the safety follow-up visit (8 weeks after the last administration of study intervention). TEAEs associated with the following situations were considered to be AESIs: (a) Infections that were severe or require IV anti-infective or operative/invasive intervention; (b) Hypoalbuminemia with albumin \<20 grams per liter (g/L) (\<2.0 grams per deciliter \[g/dL\]).

    Time frame: From Week 0 up to 8 weeks post last dose at Week 10 (up to Week 18)

07

Results

Posted Aug 22, 2025

Participant flow

Participant flow — Overall Study
MilestoneGroup 1: PlaceboGroup 2: Nipocalimab
Started2033
Completed2032
Not completed01
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryChange From Baseline in Disease Activity Index Score 28 Using C-reactive Protein (DAS28-CRP) at Week 12

Change from baseline in DAS28-CRP at Week 12 were reported. The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity, and C-reactive protein (CRP; in milligrams per liter \[mg/L\]). The set of 28 joint count was based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. Score on the DAS28 ranged from 0 to 10, where higher scores indicated more disease activity. Negative changes from baseline indicated improvement of arthritis.

Time frame:
Baseline (Week 0), Week 12
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Disease Activity Index Score 28 Using C-reactive Protein (DAS28-CRP) at Week 12
Score on a scaleGroup 1: PlaceboGroup 2: Nipocalimab
Change From Baseline in Disease Activity Index Score 28 Using C-reactive Protein (DAS28-CRP) at Week 12-0.58 (-1.24 to 0.07)-1.03 (-1.66 to -0.40)
Statistical analysis
  • Group 1: Placebo vs Group 2: Nipocalimab · ANCOVA · p = =0.224 · Least square mean difference: -0.45 · 95% CI -1.17 to 0.28
SecondaryPercentage of Participants Who Achieved American College of Rheumatology (ACR) 20 at Week 12

Percentage of participants who achieved ACR20 at Week 12 were reported. ACR20 response is defined as: greater than or equal to (\>=)20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 millimeters \[mm\], 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function as measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP.

Time frame:
Week 12
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved American College of Rheumatology (ACR) 20 at Week 12
Percentage of ParticipantsGroup 1: PlaceboGroup 2: Nipocalimab
Percentage of Participants Who Achieved American College of Rheumatology (ACR) 20 at Week 1220.0 (-1.24 to 0.07)45.5 (-1.66 to -0.40)
SecondaryPercentage of Participants Who Achieved American College of Rheumatology (ACR) 50 at Week 12

Percentage of participants who achieved ACR50 at Week 12 were reported. ACR50 response is defined as: \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function as measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP.

Time frame:
Week 12
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved American College of Rheumatology (ACR) 50 at Week 12
Percentage of ParticipantsGroup 1: PlaceboGroup 2: Nipocalimab
Percentage of Participants Who Achieved American College of Rheumatology (ACR) 50 at Week 125.0 (-1.24 to 0.07)15.2 (-1.66 to -0.40)
SecondaryPercentage of Participants Who Achieved American College of Rheumatology (ACR) 70 at Week 12

Percentage of participants who achieved ACR70 at Week 12 were reported. ACR70 response is defined as: \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function as measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP.

Time frame:
Week 12
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved American College of Rheumatology (ACR) 70 at Week 12
Percentage of ParticipantsGroup 1: PlaceboGroup 2: Nipocalimab
Percentage of Participants Who Achieved American College of Rheumatology (ACR) 70 at Week 120 (-1.24 to 0.07)12.1 (-1.66 to -0.40)
SecondaryPercentage of Participants Who Achieved American College of Rheumatology (ACR) 90 at Week 12

Percentage of participants who achieved ACR90 at Week 12 were reported. ACR90 response is defined as: \>=90% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=90% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function as measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP.

Time frame:
Week 12
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved American College of Rheumatology (ACR) 90 at Week 12
Percentage of ParticipantsGroup 1: PlaceboGroup 2: Nipocalimab
Percentage of Participants Who Achieved American College of Rheumatology (ACR) 90 at Week 120 (-1.24 to 0.07)6.1 (-1.66 to -0.40)
SecondaryPercentage of Participants Who Achieved Disease Activity Index Score 28 Using C-reactive Protein (DAS28-CRP) Remission at Week 12

Percentage of participants who achieved DAS28-CRP remission at Week 12 were reported. The DAS28 remission is defined as DAS28 -CRP value of less than (\<) 2.6 at Week 12. The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity, and CRP; in mg/L). The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, MCP1 to MCP5, PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. Score on the DAS28 ranged from 0 to 10, where higher scores indicated more disease activity. Negative changes from baseline indicated improvement of arthritis.

Time frame:
Week 12
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved Disease Activity Index Score 28 Using C-reactive Protein (DAS28-CRP) Remission at Week 12
Percentage of ParticipantsGroup 1: PlaceboGroup 2: Nipocalimab
Percentage of Participants Who Achieved Disease Activity Index Score 28 Using C-reactive Protein (DAS28-CRP) Remission at Week 1210.0 (-1.24 to 0.07)21.2 (-1.66 to -0.40)
SecondaryPercentage of Participants Who Achieved Disease Activity Index Score 28 Using C-reactive Protein (DAS28-CRP) Low Disease Activity (LDA) European League Against Rheumatism (EULAR) at Week 12

Percentage of participants who achieved DAS28-CRP LDA EULAR at Week 12 were reported. The DAS28 LDA EULAR is defined as DAS28 -CRP value of less than or equal to (\<=) 3.2 at Week 12. The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity, and C-reactive protein (CRP; in mg/L). The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, MCP1 to MCP5, PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. Score on the DAS28 ranged from 0 to 10, where higher scores indicated more disease activity. Negative changes from baseline indicated improvement of arthritis.

Time frame:
Week 12
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved Disease Activity Index Score 28 Using C-reactive Protein (DAS28-CRP) Low Disease Activity (LDA) European League Against Rheumatism (EULAR) at Week 12
Percentage of ParticipantsGroup 1: PlaceboGroup 2: Nipocalimab
Percentage of Participants Who Achieved Disease Activity Index Score 28 Using C-reactive Protein (DAS28-CRP) Low Disease Activity (LDA) European League Against Rheumatism (EULAR) at Week 1210.0 (-1.24 to 0.07)21.2 (-1.66 to -0.40)
SecondaryChange From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Week 12

Change from baseline in HAQ-DI score at Week 12 were reported. The HAQ-DI is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas: dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living, over the past week. Responses in each functional area were scored on a scale from 0 (indicating no difficulty) to 3 (inability to perform a task in that area). Overall score was computed as the sum of category scores and divided by the number of categories answered and ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability.

Time frame:
Baseline (Week 0), Week 12
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Week 12
Score on a scaleGroup 1: PlaceboGroup 2: Nipocalimab
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Week 12-0.21 (-0.45 to 0.04)-0.42 (-0.66 to -0.19)
SecondaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs)

Percentage of participants with TEAEs were reported. An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs were defined as any AE occurring at or after the initial administration of study intervention through the safety follow-up visit (8 weeks after the last administration of study intervention).

Time frame:
From Week 0 up to 8 weeks post last dose at Week 10 (up to Week 18)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
Percentage of ParticipantsGroup 1: PlaceboGroup 2: Nipocalimab
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)60.0 (-1.24 to 0.07)81.8 (-1.66 to -0.40)
SecondaryPercentage of Participants With Treatment-emergent Serious Adverse Events (TESAEs)

Percentage of participants with TESAEs were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/ incapacity, or resulted in congenital anomaly/birth defect. TESAEs were defined as any SAE occurring at or after the initial administration of study intervention through the safety follow-up visit (8 weeks after the last administration of study intervention).

Time frame:
From Week 0 up to 8 weeks post last dose at Week 10 (up to Week 18)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Treatment-emergent Serious Adverse Events (TESAEs)
Percentage of ParticipantsGroup 1: PlaceboGroup 2: Nipocalimab
Percentage of Participants With Treatment-emergent Serious Adverse Events (TESAEs)0 (-1.24 to 0.07)9.1 (-1.66 to -0.40)
SecondaryPercentage of Participants With AEs Leading to Discontinuation of Study Intervention

Percentage of participants with AEs leading to discontinuation of study intervention were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.

Time frame:
From Week 0 up to Week 10
Reported as:
Number · Percentage of Participants
Percentage of Participants With AEs Leading to Discontinuation of Study Intervention
Percentage of ParticipantsGroup 1: PlaceboGroup 2: Nipocalimab
Percentage of Participants With AEs Leading to Discontinuation of Study Intervention30.0 (-1.24 to 0.07)18.2 (-1.66 to -0.40)
SecondaryPercentage of Participants With Treatment-emergent Adverse Events of Special Interest (AESIs)

Percentage of participants with TEAEs of special interest were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs were defined as any AE occurring at or after the initial administration of study intervention through the safety follow-up visit (8 weeks after the last administration of study intervention). TEAEs associated with the following situations were considered to be AESIs: (a) Infections that were severe or require IV anti-infective or operative/invasive intervention; (b) Hypoalbuminemia with albumin \<20 grams per liter (g/L) (\<2.0 grams per deciliter \[g/dL\]).

Time frame:
From Week 0 up to 8 weeks post last dose at Week 10 (up to Week 18)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Treatment-emergent Adverse Events of Special Interest (AESIs)
Percentage of ParticipantsGroup 1: PlaceboGroup 2: Nipocalimab
Percentage of Participants With Treatment-emergent Adverse Events of Special Interest (AESIs)0 (-1.24 to 0.07)3.0 (-1.66 to -0.40)

Adverse events

Collected over All cause mortality: From screening (Week -6) up to Week 18; Serious and non-serious AEs: From Week 0 up to Week 18. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: Placebo0/20 (0%)0/20 (0%)12/20 (60%)
Group 2: Nipocalimab0/33 (0%)3/33 (9.1%)20/33 (60.6%)
Most frequent serious events
Most frequent serious events
EventGroup 1: PlaceboGroup 2: Nipocalimab
Burn InfectionInfections and infestations0/201/33
Infusion Related ReactionInjury, poisoning and procedural complications0/201/33
Deep Vein ThrombosisVascular disorders0/201/33
Most frequent other events
Showing 10 of 20
Most frequent other events
EventGroup 1: PlaceboGroup 2: Nipocalimab
Rheumatoid ArthritisMusculoskeletal and connective tissue disorders6/209/33
Covid-19Infections and infestations0/204/33
HeadacheNervous system disorders1/204/33
NauseaGastrointestinal disorders2/200/33
ChillsGeneral disorders0/202/33
FatigueGeneral disorders0/202/33
NasopharyngitisInfections and infestations1/202/33
Upper Respiratory Tract InfectionInfections and infestations1/202/33
RashSkin and subcutaneous tissue disorders0/202/33
Paraesthesia OralGastrointestinal disorders1/200/33

Baseline characteristics

Age, Continuous
Age, Continuous(years)Group 1: PlaceboGroup 2: NipocalimabTotal
Mean58.3 ± 8.5756.0 ± 12.3056.9 ± 11.01
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: PlaceboGroup 2: NipocalimabTotal
Female122436
Male8917
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group 1: PlaceboGroup 2: NipocalimabTotal
Hispanic or Latino347
Not Hispanic or Latino162945
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1: PlaceboGroup 2: NipocalimabTotal
American Indian or Alaska Native011
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American011
White183048
More than one race000
Unknown or Not Reported101
08

Study locations

28 sites
  • Arizona Arthritis & Rheumatology Associates PC
    Glendale, Arizona 85306, United States
  • Arizona Arthritis & Rheumatology Research, PLLC
    Mesa, Arizona 85210, United States
  • Arizona Arthritis & Rheumatology Research, PLLC
    Tucson, Arizona 85704, United States
  • Desert Medical Advances
    Palm Desert, California 92260, United States
  • Arthritis Care and Research Center Inc.: Smitha Reddy, MD
    Poway, California 92064, United States
  • TriWest Research Associates, LLC
    San Diego, California 92108, United States
  • Inland Rheumatology Clinical Trials, Inc.
    Upland, California 91786, United States
  • DJL Clinical Research, PLLC
    Charlotte, North Carolina 28210, United States
  • STAT Research, Inc.
    Vandalia, Ohio 45377, United States
  • Low Country Rheumatology PA
    Summerville, South Carolina 29486, United States
  • West Tennessee Research Institute
    Jackson, Tennessee 38305, United States
  • Accurate Clinical Research, Inc.
    Houston, Texas 77089, United States
  • Southwest Rheumatology Research LLC
    Mesquite, Texas 75150, United States
  • Hamburger Rheuma Forschungszentrum II
    Hamburg, 20095, Germany
  • Rheumazentrum Ratingen
    Ratingen, 40878, Germany
  • Szpital Uniwersytecki nr 2 im dr Jana Biziela w Bydgoszczy
    Bydgoszcz, 85-168, Poland
  • NZOZ Lecznica Mak-Med sc
    Nadarzyn, 05-830, Poland
  • Prywatna Praktyka Lekarska Prof Um Dr Hab Med Pawel Hrycaj
    Poznan, 61 397, Poland
  • Centrum Medyczne AMED Targowek
    Warsaw, 03 291, Poland
  • Hosp Univ A Coruna
    A Coruña, 15006, Spain
  • Hosp. Univ. de Basurto
    Bilbao, 48013, Spain
  • Hosp. Clinico Univ. de Santiago
    Santiago de Compostela, 15706, Spain
  • Hosp. Virgen Macarena
    Seville, 41009, Spain
  • Hosp. Do Meixoeiro
    Vigo, 36214, Spain
  • Western General Hospital
    Edinburgh, EH4 2XU, United Kingdom
  • Kings College Hospital NHS Trust
    London, SE5 9RS, United Kingdom
  • North Tyneside General Hospital
    Newcastle, NE29 8NH, United Kingdom
  • Haywood Hospital
    Stoke-on-Trent, ST6 7AG, United Kingdom
09

References and documents

Publications

  • Yu F, Myshkin E, Nguyen B, Bobadilla Mendez C, Cossu M, Fei K, Wang Q, Hubbard JJ, Campbell K, Ramchandren S, Rojo Cella R, Edwards R, Taylor PC, Gottenberg JE, Noaiseh G, Vu T, Antozzi C, Winthrop KL, Cuff CA, Loza MJ, Dimitrova D, Gao S. Effect of nipocalimab on IgG responses to vaccinations and viral infections in patients with IgG autoantibody-mediated diseases: Post hoc analyses of three randomized, placebo-controlled trials. Hum Vaccin Immunother. 2026 Dec;22(1):2664331. doi: 10.1080/21645515.2026.2664331. Epub 2026 May 5. PubMed 42084498 ↗
  • Taylor PC, Schett G, Huizinga TW, Wang Q, Ibrahim F, Zhou B, Liva SG, Shaik JSB, Xiong Y, Leu JH, Panchakshari RA, Loza MJ, Ma K, Dhatt H, Rojo Cella R, Karyekar CS, Cuff CA, Gao S, Fei K. Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study. RMD Open. 2024 Jun 28;10(2):e004278. doi: 10.1136/rmdopen-2024-004278. PubMed 38942592 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Aug 2022, 9 months.

Results were first posted in Aug 2025, 3 years after primary completion. A results delay was requested in Aug 2023.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 9 months is below that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2021
First posted
Aug 5, 2021
StartActual
Oct 14, 2021
Primary completionActual
Aug 10, 2022
CompletionActual
Aug 10, 2022
Results delay requested
Aug 9, 2023
Results first posted
Aug 22, 2025
Last update
Aug 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04991753
Responsible party
Sponsor
First posted
Aug 5, 2021
Start date
Oct 14, 2021
Primary completion
Aug 10, 2022
Completion
Aug 10, 2022
Results posted
Aug 22, 2025
Last update
Aug 22, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nipocalimab

Start the discussion